With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
It's official: dramatic share price jumps in response to clinical data have become more common.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.